Boston Scientific Other long-term liabilities decreased by 2.2% to $728.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 36.1%, from $535.00M to $728.00M. Over 4 years (FY 2020 to FY 2024), Other long-term liabilities shows a downward trend with a -3.8% CAGR.
other_other_accrued_liabilities_noncurrent| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $560.00M | $542.00M | $489.00M | $490.00M | $458.00M | $429.00M | $434.00M | $457.00M | $460.00M | $454.00M | $484.00M | $486.00M | $491.00M | $535.00M | $527.00M | $572.00M | $744.00M | $728.00M |
| QoQ Change | — | -3.2% | -9.8% | +0.2% | -6.5% | -6.3% | +1.2% | +5.3% | +0.7% | -1.3% | +6.6% | +0.4% | +1.0% | +9.0% | -1.5% | +8.5% | +30.1% | -2.2% |
| YoY Change | — | — | — | — | -18.2% | -20.8% | -11.2% | -6.7% | +0.4% | +5.8% | +11.5% | +6.3% | +6.7% | +17.8% | +8.9% | +17.7% | +51.5% | +36.1% |